|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
EP2654748B1
(en)
*
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
PE20190736A1
(es)
|
2012-06-13 |
2019-05-23 |
Incyte Holdings Corp |
Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
|
|
EP2934517A4
(en)
|
2012-12-20 |
2016-05-25 |
Merck Sharp & Dohme |
2-PYRIDYLOXY-3-NITRIL-4-SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
|
|
US9765057B2
(en)
|
2012-12-20 |
2017-09-19 |
Merck Sharp & Dohme Corp. |
3-ester-4 substituted orexin receptor antagonists
|
|
US9567320B2
(en)
*
|
2013-02-07 |
2017-02-14 |
Merck Patent Gmbh |
Pyridazinone-amides derivatives
|
|
RS56269B1
(sr)
*
|
2013-02-07 |
2017-11-30 |
Merck Patent Gmbh |
Makrociklični piridazinon derivati
|
|
KR102269032B1
(ko)
|
2013-04-19 |
2021-06-24 |
인사이트 홀딩스 코포레이션 |
Fgfr 저해제로서 이환식 헤테로사이클
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
KR20160115933A
(ko)
*
|
2014-01-10 |
2016-10-06 |
오리진 디스커버리 테크놀로지스 리미티드 |
Irak4 억제제로서의 인다졸 화합물
|
|
HRP20181795T1
(hr)
|
2014-01-13 |
2019-01-25 |
Aurigene Discovery Technologies Limited |
Biciklički heterociklilni derivati kao inhibitori irak4
|
|
US9969749B2
(en)
|
2014-09-30 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
US9932350B2
(en)
|
2014-09-30 |
2018-04-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
EP3200788B1
(en)
|
2014-09-30 |
2019-09-18 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
WO2016053770A1
(en)
*
|
2014-09-30 |
2016-04-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
JO3705B1
(ar)
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
EP3233840B1
(en)
|
2014-12-16 |
2018-11-21 |
Eudendron S.r.l. |
Heterocyclic derivatives modulating activity of certain protein kinases
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
PL3286181T3
(pl)
|
2015-04-22 |
2021-08-02 |
Rigel Pharmaceuticals, Inc. |
Związki pirazolowe oraz sposób wytwarzania i zastosowania tych związków
|
|
EP3195865A1
(de)
|
2016-01-25 |
2017-07-26 |
Bayer Pharma Aktiengesellschaft |
Kombinationen von irak4 inhibitoren und btk inhibitoren
|
|
UY36660A
(es)
|
2015-04-30 |
2016-11-30 |
Bayer Pharma AG |
Combinaciones de inhibidores de irak4
|
|
US10435396B2
(en)
|
2016-03-03 |
2019-10-08 |
Bayer Pharma Aktiegesellschaft |
2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
|
|
EP3219329A1
(en)
|
2016-03-17 |
2017-09-20 |
Bayer Pharma Aktiengesellschaft |
Combinations of copanlisib
|
|
PT3448849T
(pt)
|
2016-04-29 |
2020-06-30 |
Bayer Pharma AG |
Síntese de indazóis
|
|
PL3448848T3
(pl)
|
2016-04-29 |
2024-03-11 |
Bayer Pharma Aktiengesellschaft |
Postać polimorficzna N-{6-(2-hydroksypropan-2-ylo)-2-[2-(metylosulfonylo)etylo]-2H-indazol-5-ilo}-6-(trifluorometylo)pirydyno-2-karboksyamidu
|
|
AU2017272505B9
(en)
|
2016-06-01 |
2021-10-28 |
Bayer Pharma Aktiengesellschaft |
Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
|
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
|
US11419875B2
(en)
|
2017-03-31 |
2022-08-23 |
Aurigene Discovery Technologies Limited |
Compounds and compositions for treating hematological disorders
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
MX2020004155A
(es)
|
2017-10-19 |
2020-08-03 |
Bayer Animal Health Gmbh |
Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.
|
|
EP3704108B1
(en)
|
2017-10-31 |
2024-04-24 |
Curis, Inc. |
Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
GB201801226D0
(en)
|
2018-01-25 |
2018-03-14 |
Redx Pharma Plc |
Modulators of Rho-associated protein kinase
|
|
SG11202010882XA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Salts of an fgfr inhibitor
|
|
SI3788047T1
(sl)
|
2018-05-04 |
2024-11-29 |
Incyte Corporation |
Trdne oblike inhibitorja fgfr in postopki priprave le-teh
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI842978B
(zh)
|
2018-07-13 |
2024-05-21 |
美商基利科學股份有限公司 |
衍生物
|
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
HUE070387T2
(hu)
|
2019-02-11 |
2025-06-28 |
Merck Patent Gmbh |
Indazolil-izoxazol származékok betegségek, mint például rák kezelésére
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2020263967A1
(en)
*
|
2019-06-27 |
2020-12-30 |
Biogen Ma Inc. |
2h-indazole derivatives and their use in the treatment of disease
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MX2022002292A
(es)
|
2019-08-30 |
2022-06-02 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones.
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP7386576B2
(ja)
|
2019-10-02 |
2023-11-27 |
カイノス・メディスン・インコーポレイテッド |
Ｎ－（１ｈ－イミダゾール－２－イル）ベンズアミド化合物および該化合物を活性成分として含む医薬組成物
|
|
US11607416B2
(en)
|
2019-10-14 |
2023-03-21 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021084022A1
(en)
*
|
2019-10-31 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
|
|
CN114728976B
(zh)
|
2019-11-19 |
2024-08-16 |
豪夫迈·罗氏有限公司 |
用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
|
|
US12421229B2
(en)
|
2019-12-03 |
2025-09-23 |
Hoffmann-La Roche Inc. |
Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
TW202241891A
(zh)
|
2020-12-30 |
2022-11-01 |
美商凱麥拉醫療公司 |
Irak降解劑及其用途
|
|
JP2024506656A
(ja)
|
2021-02-15 |
2024-02-14 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその使用
|
|
WO2022187303A1
(en)
|
2021-03-03 |
2022-09-09 |
Rigel Pharmaceuticals, Inc. |
A method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
KR20240004476A
(ko)
|
2021-04-08 |
2024-01-11 |
쿠리스 인코퍼레이션 |
암 치료를 위한 병용 요법
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022270994A1
(ko)
|
2021-06-25 |
2022-12-29 |
한국화학연구원 |
유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
|
|
WO2023076556A1
(en)
|
2021-10-29 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|
|
JP2025513716A
(ja)
|
2022-03-23 |
2025-04-30 |
ライジェル・ファーマシューティカルズ・インコーポレイテッド |
Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物
|
|
KR102607237B1
(ko)
*
|
2023-06-07 |
2023-11-30 |
주식회사 젠센 |
신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도
|
|
WO2025036285A1
(zh)
*
|
2023-08-11 |
2025-02-20 |
深圳众格生物科技有限公司 |
一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
|